On January 31 2014, the FDA issued a safety warning on the off-label use of testosterone in men, due to old age and required a labeling change to warn for the use of testosterone, due to an increased cardiovascular- and stroke risk.
The wording of that announcement included the following lines: link here
Testosterone is FDA-approved as replacement therapy only for men, who have low testosterone levels due to disorders of the testicles, pituitary gland, or brain that cause a condition called hypogonadism. Examples of these disorders include failure of the testicles to produce testosterone because of genetic problems, or damage from chemotherapy or infection. However, FDA has become aware that testosterone is being used extensively in attempts to relieve symptoms in men who have low testosterone for no apparent reason other than aging. The benefits and safety of this use have not been established.
In addition, based on the available evidence from published studies and expert input from an Advisory Committee meeting, FDA has concluded that there is a possible increased cardiovascular risk associated with testosterone use. These studies included aging men treated with testosterone. Some studies reported an increased risk of heart attack, stroke, or death associated with testosterone treatment, while others did not.
That "advice" was dissappointing since several studies published before the warning had already shown a positive correlation to reduced risk for cardio events after therapy and subsequently even in August 2015 a very large study by the Veterans Administration concluded that successfull hormone replacement therapy has a very positive impact on cardiavascular outcomes for the patients involved-